Methods and compositions for treating polycystic ovarian syndrome
By using CRF1 antagonists to inhibit the release of ACTH, the problem of elevated androgen levels in PCOS was solved, and personalized treatment of polycystic ovary syndrome was achieved, which significantly reduced androgen levels and improved clinical symptoms.
Patent Information
- Application Number
- CN202411015454.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-08-12
- Filing Date
- 2021-08-12
- Publication Date
- 2024-11-15
AI Technical Summary
The existing treatments for polycystic ovarian syndrome (PCOS) are individualized and lack a general solution, especially for functional ovarian and hyperandrogen disorders, which are difficult to effectively reduce androgen levels.
Using CRF1 antagonists or their pharmaceutically acceptable salts, by inhibiting the corticotropin-releasing factor (CRF) receptor, reduces the stimulation of ACTH by the pituitary gland, thereby reducing androgen synthesis in the adrenal glands, and combines the acquisition of the source of excessive androgens. To develop personalized treatment plans.
It significantly reduced androgen levels such as DHEAS, ACTH, A4, 11OHA4 and 11OHT, improved the main clinical manifestations of PCOS, such as hirsiopathy and acne, and the treatment effect could be maintained for a long time.
Smart Images

Figure SMS_1 
Figure SMS_11 
Figure SMS_12
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with an application date of August 12, 2021, an application number of 202180069661.8, and an invention name of “Methods and compositions for treating polycystic ovary syndrome” (the application date of the corresponding PCT application is August 12, 2021, and the application number is PCT / US2021 / 045780).
[0002] Cross-references
[0003] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 064,863, filed on August 12, 2020; the U.S. Provisional Patent Application is incorporated herein by reference in its entirety. Background Art
[0004] Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting approximately 12% of women of childbearing age. Women with PCOS may have morphological features of polycystic ovaries, ovulatory dysfunction in the form of infrequent or prolonged menstruation, and hyperandrogenism in the form of excessive androgen levels. This complex disorder has both environmental influences, such as obesity and insulin resistance, and inappropriate endocrine signaling from the hypothalamus and pituitary as contributing factors. Hyperandrogenism manifests clinically as hirsutism and acne, and biochemically as elevated serum androgen levels. Androgens and androgen precursors can be produced and secreted by the ovaries and adrenal cortex in approximately equal amounts in response to stimulation of the ovaries by pituitary-derived luteinizing hormone (LH) and stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH), respectively. New data, PCOS patients can be classified according to the following: the source of excess androgens is mainly from the ovaries, i.e. functional ovarian hyperandrogenism (FOH), or from the adrenal glands, i.e. functional adrenal hyperandrogenism (FAH), both (FOH and FAH), or neither and can be attributed to insulin resistance / obesity, or the source is unknown. Most or about two-thirds of cases are accompanied by functional typical PCOS (PCOS-T), which is caused by typical FOH and is characterized by high responsiveness to 17-hydroxyprogesterone (17-OHP). About one-fifth of cases are accompanied by functional atypical FOH (PCOS-A), which lacks 17-OHP high responsiveness. In these two FOH groups, about one-third may suffer from FOH and FAH at the same time. About 8% of PCOS cases are attributed to obesity, and the rest are unknown or idiopathic in nature. Only about 3-5% of PCOS cases are caused by isolated FAH, accompanied by androgen responsiveness to ACTH. Summary of the invention
[0005] Adrenal androgen excess in PCOS appears to occur independently of ovarian androgen excess, suggesting that it may represent an intrinsic and possibly primary source of abnormal adrenal androgen synthesis. Adrenal androgen excess in PCOS may not result from a deficiency in a specific enzymatic step but may represent an altered responsiveness of the pituitary to corticotropin-releasing factor (CRF) and adrenocorticotropic hormone (ACTH).
[0006] In one aspect, the present disclosure provides a method for treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH+FAH) in a subject in need thereof, comprising administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof.
[0007] In another aspect, the present disclosure provides a method for treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, comprising administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof.
[0008] In another aspect, the present disclosure provides a method for treating polycystic ovary syndrome (PCOS) in a subject in need thereof, comprising administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof.
[0009] In another aspect, the present disclosure provides a method for treating polycystic ovary syndrome (PCOS) in a subject in need thereof, comprising obtaining a source of excess androgen; and administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof. In some embodiments, cosyntropin is administered at about 1 μg / m 2 In some embodiments, teicoplanin is administered at a dose of about 10 μg / m 2 In some embodiments, teicoplanin is administered at a dose of about 250 μg / m 2 In some embodiments, the source of the excess androgen is the adrenal gland. In some embodiments, the source of the excess androgen is the ovary.
[0010] In some embodiments, the CRF1 antagonist is a compound of formula (I):
[0011]
[0012] or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 R is independently ethyl or n-propyl; 3 is hydrogen, F, Cl, Br, methyl, trifluoromethyl or methoxy; R 4 For hydrogen, Br, -NR a R b, methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3.
[0013] In some embodiments, R 3 is F, Cl, Br, methyl or trifluoromethyl.
[0014] In some embodiments, R 3 It is Cl or Br.
[0015] In some embodiments, R 4 For-NR a R b , pyridin-4-yl, morpholin-4-yl or
[0016] In some embodiments, R 4 is morpholin-4-yl or
[0017] In some embodiments, R 4 For-NR a R b , and R a and R b are independently C1-C3 alkyl.
[0018] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is 3-[4-bromo-2-(2-methyl-2H-[1,2,4]triazol-3-yl)-thiazol-5-yl]-2,5-dimethyl-7-(1-propyl-butyl)-pyrazolo[1,5-a]pyrimidine.
[0019] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is 3-(4-bromo-2-(2-methyl-2H-[1,2,4]triazol-3-yl)-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine.
[0020] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is 3-(4-chloro-2-morpholin-4-yl-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine.
[0021] In some embodiments, the CRF1 antagonist is or a pharmaceutically acceptable salt thereof.
[0022] In some embodiments, the CRF1 antagonist is or a pharmaceutically acceptable salt thereof.
[0023] In some embodiments, the compound is or a pharmaceutically acceptable salt thereof.
[0024] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is selected from: Antalarmin hydrochloride, CP-154,526, CP-376395 hydrochloride, NBI 27914 hydrochloride, NBI 35965 hydrochloride, NGD 98-2 hydrochloride, Pexacerfont, R 121919 hydrochloride, SSR125543 (crinecerfont) and SN003.
[0025] In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a dose of about 5 mg to about 400 mg daily total dose. In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a dose of about 300 mg daily total dose. In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a dose of about 200 mg daily total dose. In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a dose of about 150 mg daily total dose. In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a dose of about 100 mg daily total dose. In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a dose of about 75 mg daily total dose. In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a dose of about 50 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 25 mg total daily dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is administered to the subject at a dose of about 10 mg total daily dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition.
[0026] In some embodiments, the level of adrenocorticotropic hormone (ACTH) is reduced by at least 5% from the baseline. In some embodiments, the level of adrenocorticotropic hormone (ACTH) is reduced by at least 10% from the baseline. In some embodiments, the level of dehydroepiandrosterone sulfate (DHEAS) is reduced by at least 5% from the baseline. In some embodiments, the level of dehydroepiandrosterone sulfate (DHEAS) is reduced by at least 10% from the baseline. In some embodiments, the level of androstenedione (A4) is reduced by at least 5% from the baseline. In some embodiments, the level of androstenedione (A4) is reduced by at least 10% from the baseline. In some embodiments, the level of 11β-hydroxyandrostenedione (11OHA4) is reduced by at least 5% from the baseline. In some embodiments, the level of 11β-hydroxyandrostenedione (11OHA4) is reduced by at least 10% from the baseline. In some embodiments, the level of 11β-hydroxytestosterone (11OHT) is reduced by at least 5% from the baseline. In some embodiments, the level of 11β-hydroxytestosterone (11OHT) is reduced by at least 10% from the baseline.
[0027] In some embodiments, the reduced ACTH, DHEAS, A4, 11OHA4 or 11OHT levels compared to baseline are maintained for at least 24 hours. In some embodiments, the reduced ACTH, DHEAS, A4, 11OHA4 or 11OHT levels compared to baseline are maintained for at least 4 weeks.
[0028] In another aspect, the present disclosure provides a method for treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, comprising administering a pharmaceutical composition comprising Compound 3: or a pharmaceutically acceptable salt or solvate thereof.
[0029] In another aspect, the present disclosure provides a method for treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH+FAH) in a subject in need thereof, comprising administering a pharmaceutical composition comprising Compound 3:
[0030] or a pharmaceutically acceptable salt or solvate thereof.
[0031] In some embodiments, the Compound 3 is administered at a dose of about 1 mg / day to about 400 mg / day.
[0032] In some embodiments, the pharmaceutical composition comprises about 25 mg of compound 3 or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 50 mg of compound 3 or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 75 mg of compound 3 or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 100 mg of compound 3 or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 200 mg of compound 3 or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition comprises about 1 mg to about 300 mg of compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0033] In some embodiments, the pharmaceutical composition is in the form of microparticles. In some embodiments, the average size of the microparticles is about 1 μm to about 20 μm. In some embodiments, the average size of the microparticles is about 5 μm to about 15 μm. In some embodiments, the average size of the microparticles is less than about 10 μm.
[0034] In some embodiments, the pharmaceutical composition is in the form of a capsule or tablet. In some embodiments, the capsule is a hard gelatin capsule. In some embodiments, the capsule is a soft gelatin capsule.
[0035] In some embodiments, the capsule is formed using a material selected from natural gelatin, synthetic gelatin, pectin, casein, collagen, protein, modified starch, polyvinyl pyrrolidone, acrylic acid polymers, cellulose derivatives and any combination thereof. In some embodiments, the pharmaceutical composition does not contain additional excipients. In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition is in the form of a tablet. In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
[0036] In some embodiments, the subject is a pediatric patient. In some embodiments, the subject is about 9 to about 18 years old. In some embodiments, the subject is about 8 to about 55 years old. In some embodiments, the subject is an adult patient.
[0037] In some embodiments, the subject receives treatment for about 2 weeks to about 36 weeks. In some embodiments, the subject receives treatment for about 1 month to 12 months. In some embodiments, the subject receives treatment for about 10 months to 50 years.
[0038] Additional aspects and advantages of the present disclosure will become apparent to those skilled in the art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be appreciated, the present disclosure is capable of other and different embodiments, and its several details can be modified in various obvious aspects, all without departing from the present disclosure. Therefore, the description is regarded as illustrative rather than restrictive in nature.
[0039] Incorporation by reference
[0040] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event that the publications and patents or patent applications incorporated by reference conflict with the disclosure contained in this specification, this specification is intended to supersede and / or take precedence over any such conflicting material. DETAILED DESCRIPTION
[0041] Although various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided as examples only. Without departing from the present invention, a variety of changes, modifications and substitutions may be envisioned by those skilled in the art. It should be understood that various alternatives to the embodiments of the present invention described herein may be employed.
[0042] Polycystic Ovary Syndrome (PCOS)
[0043] Polycystic ovary syndrome (PCOS) is a heterogeneous disease with multiple phenotypes and is one of the most common endocrine and metabolic disorders in women of childbearing age. PCOS was initially diagnosed and described as a oligomenorrhoea and polycystic ovary syndrome, which may be accompanied by hirsutism, acne and obesity. Considering the core diagnostic features, such as hyperandrogenism, persistent ovulatory dysfunction and polycystic ovarian morphology (PCOM), there are multiple diagnostic criteria for adolescent and adult patients. The exact cause of this disease is not fully understood, however, genetic and environmental factors seem to play a role in causing this disease. Typically, PCOS manifests as a phenotype that reflects a self-perpetuating vicious cycle involving neuroendocrine, metabolic and ovarian dysfunction, and is characterized by excessive secretion of ovarian and / or adrenal androgens. For example, intrinsic ovarian factors (such as altered steroidogenesis) and ovarian external factors (such as hyperinsulinemia) can lead to excessive ovarian androgen production. The classic ovarian phenotype of ovarian enlargement with beaded morphology and membranous stromal hyperplasia reflects androgen exposure; this morphology is also observed in women with congenital adrenal hyperplasia (CAH).
[0044] In an attempt to understand the pathophysiology of PCOS, it is important to understand the molecular basis of steroidogenesis and androgen sources, production, and physiology. Under normal circumstances in women, the ovaries and adrenals contribute approximately equally to testosterone production. Approximately half of testosterone is derived from direct testosterone secretion from the ovaries and adrenals, while the other half is produced through peripheral conversion of circulating androstenedione, which itself is derived from approximately equal ovarian and adrenal secretions. Androgen production is not subject to direct negative feedback regulation by the female neuroendocrine system, as is the case with estradiol and cortisol secretion. Androgens are secreted by the ovaries and adrenals in response to their respective endocrine-stimulating hormones, LH and ACTH. The zona reticularis of the adrenal glands resembles the theca cell compartment of the ovary in expressing the core enzymatic pattern of androgen production.
[0045] PCOS patients can be functionally classified into different subtypes based on the sources of androgen excess listed in Table 1 below. Androgen excess can come from the ovaries, adrenals, both, or neither. Primary PCOS is the most common variant of PCOS without any known cause, and proposed theories suggest that functional ovarian hyperandrogenism (FOH) as well as hypothalamic-pituitary-ovarian (HPO) axis dysfunction may be underlying causes. In addition, functional adrenal hyperandrogenism (FAH) in addition to HPO axis disorders may explain certain groups of PCOS patients. PCOS patients with primary FAH may experience an average increase of 50% in adrenal gland volume, which correlates with the severity of hyperandrogenism.
[0046] Table 1 Functional classification of PCOS based on the source of androgen excess
[0047]
[0048] The test procedures for determining the source of androgens are listed in Table 2 below. Ovarian hyperandrogenism in PCOS is directly demonstrated by the GnRHag test or the hCG test and is used in conjunction with the dexamethasone androgen suppression test (DAST). The GnRHag test determines the coordinated function of the ovarian follicles. Leuprolide acetate (Leuprolide) 10 μg / kg subcutaneous injection (sc) (or any other short-acting GnRHag at an equivalent dose) stimulates endogenous LH and FSH release, which peaks at 3-4 hours and lasts for 24 hours; this in turn stimulates increased secretion of sex steroids and their precursors, with serum levels peaking at 18-24 hours. In the absence of evidence of steroidogenic blockade, an elevated 17OHP response is a typical manifestation of PCOS. Ovarian steroidogenic enzyme deficiency (very rare) can be detected by an abnormal pattern of steroid intermediates in response to the test. hCG is an LH analog: 5000 IU intramuscularly stimulates a steroidogenic response, which is equivalent to the GnRHag test at 24 hours. DAST indirectly tests the ovarian source of androgens by suppressing the production of ACTH-dependent androgens. In the setting of normal adrenal cortical suppression, an abnormal increase in serum testosterone after DAST indicates an ACTH-independent androgen source, usually ovarian.
[0049] Adrenal hyperandrogenism can be demonstrated by a rapid ACTH test: intravenous administration of tacrolimus with a peak steroid response at 15-60 minutes. Elevated DHEA after this test indicates an ACTH-dependent androgen source, usually the adrenal gland. This test can be performed with tacrolimus 250 μg, which is a supramaximal dose. Lower doses of tacrolimus (10 μg / m 2 ), which causes a similar peak response. A low-dose ACTH test (1.0-μg tadalafil) can be used and is probably more physiological. It usually causes a response that is almost as large as the peak response that tapers off rapidly and, in PCOS, does not cause such a widespread steroid intermediate elevation as the larger doses.
[0050] Table 2 Methods for determining the source of androgen excess in women
[0051]
[0052] Corticotropin-releasing factor
[0053] Currently, there is no single universal treatment for PCOS available. Therefore, current treatments are often individualized and adapted to the actual needs of individual patients. In addition, treatment may be symptom-oriented. For example, the goal of drug therapy may include androgen excess. For PCOS patients with elevated adrenal androgens, FOH+FAH and PCOS-FAH patients, in some embodiments, drug therapy can be used, such as corticotropin-releasing factor (CRF) receptor antagonists that target ACTH production.
[0054] Corticotropin-releasing factor (CRF) is a 41 amino acid peptide that is the major physiological regulator of proopiomelanocortin (POMC)-derived peptide secretion from the anterior pituitary. In addition to its endocrine effects at the pituitary, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a variety of autonomic, electrophysiological, and behavioral effects consistent with neurotransmitter or neuromodulator action in the brain. There is also evidence that CRF plays an important role in integrating the immune system's response to physiological, psychological, and immunological stressors.
[0055] CRF has been implicated in psychiatric and neurological disorders including depression and anxiety, as well as the following: Alzheimer's disease, Huntington's disease, progressive supranuclear palsy, amyotrophic lateral sclerosis, Parkinson's disease, epilepsy, migraine, alcohol and substance abuse and related withdrawal symptoms, obesity, metabolic syndrome, congenital adrenal hyperplasia (CAH), Cushing's disease, hypertension, stroke, irritable bowel syndrome, stress ulcers, premenstrual syndrome, sexual dysfunction, premature birth, inflammatory disorders, allergies, multiple sclerosis, visceral pain, sleep disorders, pituitary tumors or ectopic pituitary tumors, chronic fatigue syndrome, and fibromyalgia.
[0056] CRF is considered to be the major physiological regulator of basal and stress-induced release of adrenocorticotropic hormone ("ACTH"), beta-endorphin, and other pro-opiomelanocortin ("POMC")-derived peptides from the anterior pituitary. CRF secretion causes corticotropin release of ACTH in the anterior pituitary by binding to the CRF1 receptor (a member of the class B family of G protein-coupled receptors).
[0057] Due to the physiological significance of CRF1, the development of bioactive small molecules with significant CRF receptor binding activity and capable of antagonizing the CRF1 receptor remains a desirable goal and has been the subject of ongoing research and development for the treatment of anxiety disorders, depression, irritable bowel syndrome, post-traumatic stress disorder and substance abuse, as well as congenital adrenal hyperplasia.
[0058] The pituitary hormone ACTH, under the control of hypothalamic corticotropin-releasing factor (CRF), stimulates cholesterol uptake and drives the synthesis of pregnenolone, thereby initiating steroidogenesis in the adrenal glands. The adrenal cortex consists of three regions that produce different classes of hormones, many of which are driven by ACTH-mobilized cholesterol through this pathway. The middle layer—the zona reticularis—is responsible for the production of androgens such as DHEA, DHEAS, and androstenedione (A4), a precursor to testosterone (T) and dihydrotestosterone (DHT). This layer is also responsible for the production of 11-oxoandrogens, 11β-hydroxyandrostenedione (11OHA4) and 11β-hydroxytestosterone (11OHT), which are the main biologically active androgens, especially in women. Because of unknown reasons for elevated androgens in PCOS patients, the zona reticularis exhibits hyperresponsiveness to ACTH, resulting in excessive levels of DHEA, DHEAS, 11OHA4, 11OHT, and A4. Excessive ACTH stimulation leads to hypertrophy of the zona reticularis, which results in adrenal hyperplasia, clinically manifesting as classic signs of PCOS and hyperandrogenism. Reducing stimulation of pituitary ACTH secretion by inhibiting the CRF1 receptor is expected to reduce excessive androgen synthesis in the adrenal ACTH-responsive areas in PCOS. Normalization of elevated androgen levels in the short term is expected to improve the cardinal features of PCOS - hirsutism, acne, and menstrual irregularities - in the long term.
[0059] Some definitions
[0060] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the embodiments described herein, certain preferred methods, devices and materials are now described.
[0061] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an excipient" is a reference to one or more excipients and equivalents thereof known to those skilled in the art, and so forth.
[0062] The term "about" is used to indicate that a value includes a 10% level of error for the device or method being employed to determine the value.
[0063] Use of the term "or" in the claims is intended to mean "and / or" unless explicitly stated to refer only to alternatives or the alternatives are mutually exclusive, but the present disclosure supports definitions referring only to alternatives and to "and / or."
[0064] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting only of carbon atoms and hydrogen atoms, which does not contain unsaturation, and preferably has one to five carbon atoms (i.e., C1-C5 alkyl). In some embodiments, the alkyl includes one to four carbon atoms (i.e., C1-C4 alkyl). In some embodiments, the alkyl includes one to three carbon atoms (i.e., C1-C3 alkyl). In some embodiments, the alkyl includes one to two carbon atoms (i.e., C1-C2 alkyl). In some embodiments, the alkyl includes one carbon atom (i.e., C1 alkyl). In certain embodiments, the alkyl is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl) and 1-pentyl (n-pentyl). The alkyl is connected to the rest of the molecule by a single bond. Unless otherwise specifically stated in the specification, the alkyl is optionally substituted by one or more substituents, such as those described herein.
[0065] The terms "comprising," "having," and "including" are open-ended linking verbs. Any form or tense of one or more of these verbs is also open-ended. For example, any method that "comprising," "having," or "includes" one or more steps is not limited to having only those one or more steps, and also encompasses other unlisted steps.
[0066] When used in conjunction with treatment, "administering" refers to systemic administration of a therapeutic agent or local administration of a therapeutic agent, such as direct administration into or onto a target tissue, or to administration of a therapeutic agent to a patient, whereby the therapeutic agent actively affects its target tissue. "Administration" of a pharmaceutical composition can be achieved by injection, topical administration, and oral administration, or by other methods alone or in combination with other known techniques.
[0067] By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
[0068] The term "pharmaceutical composition" means a composition comprising at least one active ingredient (such as a steroid or a pharmaceutically acceptable salt thereof or a CRF1 antagonist or a pharmaceutically acceptable salt thereof), whereby the composition is suitable for studying a specified efficacy outcome in a mammal (such as but not limited to a human). One of ordinary skill in the art will understand and appreciate the techniques suitable for determining whether an active ingredient has a desired efficacy outcome based on the needs of the technician.
[0069] The term "supraphysiological" describes glucocorticoid dosage levels that are above the daily glucocorticoid requirement (production rate) found in healthy individuals.
[0070] The term "physiological amount" describes the glucocorticoid dosage level found in healthy individuals that meets the daily glucocorticoid requirement (production rate).
[0071] As used herein, term " hydrocortisone equivalent " is understood by those skilled in the art as the conversion calculation that needs to be considered when replacing another kind of glucocorticoid with a kind of glucocorticoid, because the effect effectiveness and the duration of various glucocorticoids can change.Therefore, term " hydrocortisone equivalent " is the standard for comparing glucocorticoid effectiveness.
[0072] As used herein, "therapeutically effective amount" or "effective amount" refers to the amount of an active compound or agent that elicits a biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which biological or medicinal response includes one or more of the following: (1) preventing disease; for example, preventing the disease, condition or disorder in an individual who is susceptible to the disease, condition or disorder but does not yet experience or display the pathology or symptomology of the disease, (2) inhibiting disease; for example, inhibiting the disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition or disorder (i.e., arresting further development of the pathology and / or symptomology), and (3) ameliorating disease; for example, ameliorating the disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition or disorder (i.e., reversing the pathology and / or symptomology).
[0073] As used herein, the term "treatment" refers to therapeutic treatment in some embodiments, and to preventive measures in other embodiments, wherein the purpose is to prevent or slow down (mitigate) an undesirable physiological condition, disorder or disease, or to obtain a beneficial or desired clinical result. For the purposes described herein, beneficial or desired clinical results include, but are not limited to: relief of symptoms; relief of the degree of the condition, disorder or disease; stabilization (i.e., no deterioration) of the condition, disorder or disease state; delayed onset or slowed development of the condition, disorder or disease; improvement of the condition, disorder or disease state; and relief (whether partial or complete) (whether detectable or undetectable) or enhancement or improvement of the condition, disorder or disease. Treatment includes inducing a clinically significant response without producing excessive levels of side effects. Treatment also includes extending survival compared to the expected survival without treatment. The preventive benefits of treatment include preventing the condition, delaying the progression of the condition, stabilizing the condition, or reducing the likelihood of the condition occurring. As used herein, "treatment" includes prevention in some embodiments.
[0074] Compound
[0075] Disclosed herein are CRF1 antagonists or pharmaceutically acceptable salts thereof, such as antalamine hydrochloride, CP-154,526, CP-376395 hydrochloride, NBI 27914 hydrochloride, NBI 35965 hydrochloride, NGD 98-2 hydrochloride, pexaserfon, R121919 hydrochloride, SN003 and SSR125543 (Careserfon).
[0076] In one aspect, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is selected from: n-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride (Antaramin hydrochloride), n-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride (Pfizer CP154526), N-(1-ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-4-pyridinamine hydrochloride (Pfizer CP 376395 hydrochloride), 5-chloro-N-(cyclopropylmethyl)-2-methyl-n-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride (NBI27914 hydrochloride), (7S)-6-(cyclopropylmethyl)-2-(2,4-dichlorophenyl)-7-ethyl-7,8-dihydro-4-methyl-6H-1,3,6,8a-tetraazaacenaphthylene hydrochloride (NBI35965 hydrochloride), N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl-2-pyrazinamine hydrochloride (NGD 98-2 hydrochloride), 8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo[1,5-a]-1,3,5-triazine-4-amine (pesafen), 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropylpyrazolo[1,5-a]pyrimidin-7-amine hydrochloride (R 121919 hydrochloride) and N-(4-methoxy-2-methylphenyl)-1-[1-(methoxymethyl)propyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine (SN003), (S)-4-(2-chloro-4-methoxy-5-methylphenyl)-N-(2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-(prop-2-yn-1-yl)thiazol-2-amine (SSR125543).
[0077] Disclosed herein is a compound of formula (I):
[0078]
[0079] or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 R is independently ethyl or n-propyl; 3 is H, Cl, Br, methyl, trifluoromethyl or methoxy; R 4 H, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, and
[0080] R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3.
[0081] In some embodiments, R 1 and R 2 In some embodiments, R 1 is ethyl and R 2 In some embodiments, R 1 is n-propyl and R 2 In some embodiments, R 1 and R 2 In some embodiments, R 1 and R 2 All are n-propyl.
[0082] In some embodiments, R 3 is hydrogen, Cl, Br, methyl or trifluoromethyl. In some embodiments, R 3 is hydrogen, Cl, Br or methyl. In some embodiments, R 3 is hydrogen, Cl or Br. In some embodiments, R 3 In some embodiments, R 3 is Cl. In some embodiments, R 3 For Br.
[0083] In some embodiments, R 4 For hydrogen, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, In some embodiments, R 4 Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, In some embodiments, R 4 For-NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl or In some embodiments, R 4 For-NR a R b , n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl or In some embodiments, R 4 For-NR a R b , pyridin-4-yl, morpholin-4-yl or In some embodiments, R 4 is morpholin-4-yl or In some embodiments, R 4 In some embodiments, R 4 for In some embodiments, R 4 For-NR a R b , and R a and R b are independently C1-C3 alkyl.
[0084] Disclosed herein is a compound of formula (II):
[0085]
[0086] or a pharmaceutically acceptable salt thereof, wherein R 3 is H, Cl, Br, methyl, trifluoromethyl or methoxy; R 4 H, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, And R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3-CH2CH2NHCH2CH2CH3.
[0087] Disclosed herein is a compound of formula (III):
[0088]
[0089] or a pharmaceutically acceptable salt thereof, wherein R 1 and R2 is n-propyl; R 3 is H, Cl, Br, methyl, trifluoromethyl or methoxy; R 4 H, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, And R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3.
[0090] Disclosed herein is a compound of formula (IV):
[0091]
[0092] or a pharmaceutically acceptable salt thereof, wherein R 3 is Cl, Br, methyl, trifluoromethyl or methoxy; R 4 H, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, And R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3.
[0093] For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 3 It can be hydrogen, Cl, Br, methyl, trifluoromethyl or methoxy.
[0094] (II), (III) and (IV) or a pharmaceutically acceptable salt thereof, R 3 For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 3 For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 3 For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 3 It can be Cl. For formula (I), (II), (III)
[0095] and (IV) or a pharmaceutically acceptable salt thereof, R 3 It can be Br. For formula (I),
[0096] (II), (III) and (IV) or a pharmaceutically acceptable salt thereof, R 3 It may be methyl.
[0097] For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 is Br, methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 is Br, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 is Br, acetylamino, pyridin-4-yl, morpholin-4-yl, For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 is Br, pyridin-4-yl, morpholin-4-yl, For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 is pyridin-4-yl, morpholin-4-yl, For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 is morpholin-4-yl, For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 for For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 for For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 for For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 for For the compounds or pharmaceutically acceptable salts of formula (I), (II), (III) and (IV), R 4 It is morpholin-4-yl.
[0098] Disclosed herein is 3-[4-bromo-2-(2-methyl-2H-[1,2,4]triazol-3-yl)-thiazol-5-yl]-2,5-dimethyl-7-(1-propyl-butyl)-pyrazolo[1,5-a]pyrimidine (Compound 1) or a pharmaceutically acceptable salt thereof:
[0099]
[0100] Disclosed herein is 3-(4-bromo-2-(2-methyl-2H-[1,2,4]triazol-3-yl)-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine (Compound 2) or a pharmaceutically acceptable salt thereof:
[0101]
[0102] Disclosed herein is 3-(4-chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine (or alternatively, 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine) (Compound 3) or a pharmaceutically acceptable salt thereof:
[0103]
[0104] In some embodiments, 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine is referred to as Compound 3. In some embodiments, 3-(4-chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine is referred to as Compound 3.
[0105] In one aspect, the CRF1 antagonist or a pharmaceutically acceptable salt thereof can be astressin. Astressin generally refers to a non-selective corticotropin-releasing hormone antagonist that reduces the synthesis of ACTH and Cortisol.
[0106] Pharmaceutical composition
[0107] Disclosed herein are pharmaceutical compositions comprising compounds described herein or pharmaceutically acceptable salts thereof. In certain embodiments, the composition comprises a steroid as described above or a pharmaceutically acceptable salt thereof and a CRF1 antagonist or a pharmaceutically acceptable salt thereof. In some embodiments, the steroid or a pharmaceutically acceptable salt thereof is an exogenous glucocorticoid (GC) or a pharmaceutically acceptable salt thereof.
[0108] Dosage form
[0109] In some embodiments, the pharmaceutical composition described herein is provided in unit dosage form. As used herein, "unit dosage form" is suitable for being administered to an animal (preferably, a mammal) subject in a single dose according to good medical practice. Compositions containing a certain amount of compounds described herein or pharmaceutically acceptable salts. However, preparing a single dosage form or unit dosage form does not mean that the dosage form is administered once a day or once per treatment course. It is envisioned that such dosage forms are administered once, twice, three times or more a day, and can be administered in an infusion manner for a period of time (e.g., about 30 minutes to about 2-6 hours), or can be administered in a continuous infusion manner, and can be given more than once during a treatment course, but single administration is not explicitly excluded.
[0110] The pharmaceutical composition is applied in a manner suitable for the disease to be treated (or prevented). Suitable dosage, suitable duration and frequency of application will be determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient and the method of administration. Usually, suitable dosage and treatment regimen provide compositions in an amount sufficient to provide treatment and / or prevention benefits (e.g., clinical results improve, such as complete or partial relief more frequently, or disease-free and / or overall survival longer or symptom severity alleviated). Optimal dose is usually determined using experimental models and / or clinical trials. Optimal dose depends on the patient's body mass, body weight or blood volume.
[0111] In some embodiments, the pharmaceutical compositions described herein are formulated as oral dosage forms. Suitable oral dosage forms include, for example, tablets, pills, pouches, or capsules. In some embodiments, the pharmaceutical composition comprises one or more additional pharmaceutically acceptable excipients. For a list of pharmaceutically acceptable excipients, see, for example, Remington: The Science and Practice of Pharmacy (Gennaro, 21st Edition, Mack Pub. Co., Easton, PA (2005)).
[0112] capsule
[0113] In some embodiments, the pharmaceutical composition is formulated as a capsule. In some embodiments, the pharmaceutical composition is formulated as a hard gel capsule. In some embodiments, the pharmaceutical composition is formulated as a soft gel capsule.
[0114] In some embodiments, the capsule is formed using materials including but not limited to natural or synthetic gelatin, pectin, casein, collagen, protein, modified starch, polyvinyl pyrrolidone, acrylic polymer, cellulose derivatives or any combination thereof. In some embodiments, the capsule is formed using preservatives, colorants and opacifiers, flavorings and sweeteners, sugar, gastroresistant substances or any combination thereof. In some embodiments, the capsule is coated. In some embodiments, the coating covering the capsule includes but is not limited to immediate release coating, protective coating, enteric coating or delayed release coating, sustained release coating, barrier coating, seal coating or a combination thereof. In some embodiments, the capsule herein is hard or soft. In some embodiments, the capsule is seamless. In some embodiments, the capsule is disassembled so that the particles are sprinkled on soft food and swallowed without chewing. In some embodiments, the shape and size of the capsule may also vary. Examples of capsule shapes include but are not limited to round, oval, tubular, rectangular, twist off or non-standard shapes. The size of the capsule may vary according to the volume of the particles. In some embodiments, the size of the capsule is adjusted based on the volume of particles and powders. Hard gelatin capsules or soft gelatin capsules can be manufactured as a single body unit including a standard capsule shape according to conventional methods. Single body soft gelatin capsules can generally be provided with a size of, for example, 3 to 22 drops (1 drop is equal to 0.0616 ml) and an oval, rectangular or other shape. Gelatin capsules can also be manufactured as, for example, a sealed or unsealed two-piece hard gelatin capsule of a standard shape and various standard sizes (usually named (000), (00), (0), (1), (2), (3), (4) and (5)) according to conventional methods. The maximum number corresponds to the minimum size. In some embodiments, pharmaceutical compositions described herein (e.g., capsules) are swallowed as a whole.
[0115] In some embodiments, the capsule comprises one or more pharmaceutically acceptable excipients. In some embodiments, the capsule contains no additional excipients.
[0116] In some embodiments, capsules are developed, manufactured, and commercialized for insoluble drug substances. In some embodiments, a drug substance is insoluble if the solubility in water is less than 0.002 mg / mL. In some embodiments, the dosage strength of the capsule does not exceed 200 mg. In some embodiments, the drug substance in the capsule is immediately released in the dissolution medium using USP apparatus I. In some embodiments, the drug substance in the capsule is immediately released in the dissolution medium using USP apparatus II.
[0117] tablet
[0118] Poorly soluble drugs may be difficult to formulate using standard techniques such as high shear wet granulation. The optimal delivery of poorly soluble drugs may require complex techniques, such as solid solution amorphous dispersions (hot melt extrusion or spray drying), nanoformulations, or lipid-based formulations. Hydrophobic APIs can be considered as poorly soluble according to USP standards, and are known to be difficult to granulate with water and other excipients. This may be due to the fact that most known excipients for immediate release formulations are water-soluble or water-swellable. Tablets of poorly soluble high-dose APIs may require high concentrations of APIs. However, when the drug concentration increases to above a certain level, particle formation may become increasingly difficult. In addition, at a certain drug loading, particle formation may become impossible.
[0119] In some embodiments, the pharmaceutical composition is formulated as a tablet.
[0120] In some embodiments, tablets are optionally prepared by compression, molding or extrusion with one or more pharmaceutically acceptable excipients. In some embodiments, compressed tablets are prepared by compressing a compound or a pharmaceutically acceptable salt as described herein in a free-flowing form optionally mixed with a pharmaceutically acceptable excipient. In some embodiments, molded tablets are prepared by molding a mixture of a powdered compound or a pharmaceutically acceptable salt as described herein moistened with an inert liquid diluent. In some embodiments, tablets are prepared by hot melt extrusion. In some embodiments, extruded tablets are prepared by forcing a mixture containing a compound or a pharmaceutically acceptable salt as described herein through an orifice or a mold under controlled conditions. In some embodiments, the tablet is coated or scored. In some embodiments, tablets are formulated to provide a sustained release or controlled release of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, tablets are developed, manufactured and commercialized for insoluble bulk drugs. In some embodiments, if the solubility in water is less than 0.002 mg / mL, the bulk drug is insoluble. In some embodiments, the dosage strength of the tablet does not exceed 200 mg. In some embodiments, the drug substance in the tablet is immediately released in the dissolution medium using USP Apparatus I. In some embodiments, the drug substance in the tablet is immediately released in the dissolution medium using USP Apparatus II.
[0121] In some embodiments, the tablet size is less than about 1000 mg, less than about 800 mg, less than about 600 mg, less than about 400 mg, less than about 200 mg, less than about 100 mg, or less than about 50 mg. In some embodiments, the dosage strength of the tablet is greater than about 10 mg, greater than about 50 mg, greater than about 100 mg, greater than about 150 mg, greater than about 200 mg, or greater than about 250 mg. In some embodiments, for a dosage strength greater than about 50 mg, the tablet size is less than about 1000 mg. In some embodiments, for a dosage strength greater than about 100 mg, the tablet size is less than 800 mg. In some embodiments, for a dosage strength greater than about 150 mg, the tablet size is less than 600 mg. In some embodiments, for a dosage strength greater than about 200 mg, the tablet size is less than 400 mg. In some embodiments, for a dosage strength of 100 mg, the tablet size is less than 400 mg. In some embodiments, for a dosage strength of 50 mg, the tablet size is less than 200 mg. In some embodiments, for a 10 mg dosage strength, the tablet size is less than 50 mg.
[0122] In some embodiments, more than about 20% of the tablet is dissolved in a conventional dissolution medium. In some embodiments, more than about 40% of the tablet is dissolved in a conventional dissolution medium. In some embodiments, more than about 50% of the tablet is dissolved in a conventional dissolution medium. In some embodiments, more than about 60% of the tablet is dissolved in a conventional dissolution medium. In some embodiments, more than about 70% of the tablet is dissolved in a conventional dissolution medium. In some embodiments, more than about 80% of the tablet is dissolved in a conventional dissolution medium. In some embodiments, more than about 20% of the tablet is dissolved in a conventional dissolution medium in less than 24 hours. In some embodiments, more than about 20% of the tablet is dissolved in a conventional dissolution medium in less than 12 hours. In some embodiments, more than about 20% of the tablet is dissolved in a conventional dissolution medium in less than 6 hours. In some embodiments, more than about 20% of the tablet is dissolved in a conventional dissolution medium in less than 3 hours. In some embodiments, more than about 20% of the tablet is dissolved in a conventional dissolution medium in less than 2 hours. In some embodiments, more than about 20% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes. In some embodiments, more than about 40% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes. In some embodiments, more than about 50% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes. In some embodiments, more than about 60% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes. In some embodiments, more than about 70% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes. In some embodiments, more than about 80% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes. In some embodiments, more than about 90% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes. In some embodiments, more than about 100% of the tablet is dissolved in a conventional dissolution medium in less than 60 minutes.
[0123] In some embodiments, tablets are produced on a commercial scale.
[0124] In some embodiments, tablets include one or more pharmaceutically acceptable excipients.
[0125] In some embodiments, tablets are coated with coating materials (e.g., sealants). In some embodiments, the coating materials are water-soluble. In some embodiments, the coating materials include polymers, plasticizers, pigments, or any combination thereof. In some embodiments, the coating materials are in the form of film coatings, such as glossy films, non-pH dependent film coatings, aqueous film coatings, dry powder film coatings (e.g., complete dry powder film coatings), or any combination thereof. In some embodiments, the coating materials are highly viscous. In some embodiments, the coating materials provide low water permeability levels. In some embodiments, the coating materials provide oxygen barrier protection. In some embodiments, the coating materials allow immediate disintegration to achieve rapid release of compounds described herein or pharmaceutically acceptable salts. In some embodiments, the coating materials are colored, transparent, or white. In some embodiments, the coating is an enteric coating. Exemplary coating materials include, but are not limited to, polyvinyl pyrrolidone, polyvinyl alcohol, acrylate-methacrylic acid copolymer, methacrylate-methacrylic acid copolymer, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, cellulose acetate trimellitate, sodium alginate, zein, and any combination thereof.
[0126] Pharmaceutically acceptable excipients
[0127] In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable excipient. In some embodiments, the composition does not contain a pharmaceutically acceptable excipient. As used herein, the term "pharmaceutically acceptable excipient" refers to one or more compatible solids or encapsulated materials suitable for administration to mammals. As used herein, the term "compatible" means that the components of the composition can be mixed with the subject compound and can be mixed with each other in a manner that there is no interaction, and the interaction will significantly reduce the drug efficacy of the composition under ordinary use conditions. In some embodiments, the purity of the pharmaceutically acceptable excipient is high enough and the toxicity is low enough to make it suitable for preferably being administered to the treated animal, preferably a mammal.
[0128] Some examples of substances that can serve as pharmaceutically acceptable excipients include:
[0129] ■ Amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. In some embodiments, the amino acid is arginine. In some embodiments, the amino acid is L-arginine.
[0130] ■ Monosaccharides such as glucose (dextrose), arabinose, mannitol, fructose (levulose), and galactose.
[0131] ■ Cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose and methylcellulose.
[0132] ■ Solid lubricants such as talc, stearic acid, magnesium stearate and sodium stearyl fumarate. ■ Polyols such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol.
[0133] ■ Emulsifiers, such as polysorbates.
[0134] ■Wetting agents, such as sodium lauryl sulfate, Span, alkyl sulfates and alkyl ethoxylated sulfates.
[0135] ■ Diluents, such as calcium carbonate, microcrystalline cellulose, calcium phosphate, starch, pregelatinized starch, sodium carbonate, mannitol and lactose.
[0136] ■ Binders, such as starch (corn starch and potato starch), gelatin, sucrose, hydroxypropyl cellulose (HPC), polyvinyl pyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC).
[0137] ■ Disintegrants, such as starch and alginic acid.
[0138] ■ Super disintegrants such as ac-di-sol, croscarmellose sodium, sodium starch glycolate and crospovidone.
[0139] ■ Glidants, such as silicon dioxide.
[0140] ■ Colorants, such as FD&C dyes.
[0141] ■ Sweeteners and flavorings, such as aspartame, saccharin, menthol, peppermint, and fruit flavorings.
[0142] ■ Preservatives such as benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, parabens, and sodium benzoate.
[0143] ■Tonicity adjusters, such as sodium chloride, potassium chloride, mannitol, and glycerol.
[0144] ■ Antioxidants such as sodium bisulfite, sodium bisulfite acetone, sodium formaldehyde sulfoxylate, thiourea and EDTA.
[0145] ■ pH adjusters such as NaOH, sodium carbonate, sodium acetate, HCl and citric acid.
[0146] ■ Cryoprotectants such as sodium or potassium phosphate, citric acid, tartaric acid, gelatin, and carbohydrates (such as dextrose, mannitol, and dextran).
[0147] ■ Cationic surfactants such as cetrimide, benzalkonium chloride and cetylpyridinium chloride.
[0148] ■ Anionic surfactants such as alkyl sulfates, alkyl ethoxylated sulfates, fatty acid salts, carboxylates, sulfates and sulfonates.
[0149] ■ Nonionic surfactants, such as polyoxyethylene derivatives, polyoxypropylene derivatives, polyol derivatives, polyol esters, polyoxyethylene esters, poloxamers, glycol esters, glycerides, sorbitan derivatives, polyethylene glycol (PEG-40, PEG-50, PEG-55) and ethers of fatty alcohols.
[0150] ■ Organic materials such as carbohydrates and modified carbohydrates, lactose, α-lactose monohydrate, spray-dried lactose and anhydrous lactose, starch and pregelatinized starch, sucrose, mannitol, sorbitol, cellulose, powdered cellulose and microcrystalline cellulose.
[0151] ■ Inorganic materials such as calcium phosphates (anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate and calcium phosphate). ■ Co-processing diluents.
[0152] ■ Surfactants, such as sodium lauryl sulfate.
[0153] ■Compression aid.
[0154] ■ Anti-sticking agents, such as silica and talc.
[0155] quantity
[0156] In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 500 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 400 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 300 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 200 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 100 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 90 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 80 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 70 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 60 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 50 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 40 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 30 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 20 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 1 mg to about 10 mg of a compound or a pharmaceutically acceptable salt as described herein.
[0157] In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 500 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 400 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 300 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 200 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 100 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 90 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 80 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 70 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 60 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 50 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 40 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 30 mg of a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the pharmaceutical composition in the form of a tablet or capsule contains about 10 mg to about 20 mg of a compound or a pharmaceutically acceptable salt as described herein.
[0158] Particle size
[0159] In some embodiments, the pharmaceutical composition in the form of a tablet or capsule comprises a compound or a pharmaceutically acceptable salt described herein in the form of microparticles. In some embodiments, the microparticles have an average size of about 1 μm to about 100 μm. In some embodiments, the microparticles have an average size of about 1 μm to about 50 μm. In some embodiments, the microparticles have an average size of about 1 μm to about 30 μm. In some embodiments, the microparticles have an average size of about 1 μm to about 20 μm. In some embodiments, the microparticles have an average size of about 5 μm to about 15 μm. In some embodiments, the microparticles have an average size of about 1 μm to about 10 μm. In some embodiments, the microparticles have an average size of about 3 μm to about 10 μm. In some embodiments, the microparticles have an average size of about 4 μm to about 9 μm.
[0160] Treatment
[0161] Disclosed herein are methods for treating polycystic ovary syndrome (PCOS) in a subject in need thereof, comprising administering a compound or a pharmaceutically acceptable salt as described herein. In some embodiments, the subject in need thereof suffers from PCOS-FAH. In some embodiments, the subject in need thereof suffers from PCOS-FOH+FAH. In some embodiments, the methods described herein result in a reduction in hormone levels. Such hormones include deoxycorticosterone, 11-deoxycortisol, cortisol, corticosterone, pregnenolone, 17α-hydroxypregnenolone, progesterone, 17-OHP, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androstenediol, androstenedione (A4), testosterone (T), dihydrotestosterone (DHT), estrone, estradiol, estriol, 11β-hydroxyandrostenedione (11OHA4), 11β-hydroxytestosterone (11OHT), 11-ketoandrostenedione (11KA4), 11-ketotestosterone (11KT), 11β-hydroxy-5α-androstenedione (11OHDHA4), 11-keto-5α-androstenedione (11KDHA4), 11β-hydroxydihydrotestosterone (11OHDHT), 11-ketodihydrotestosterone (11KDHT) and ACTH. In some embodiments, the methods described herein result in a reduction in 17-OHP levels. In some embodiments, the methods described herein result in a reduction in A4 levels. In some embodiments, the methods described herein result in a reduction in ACTH levels. In some embodiments, the methods described herein result in a reduction in DHEA levels. In some embodiments, the methods described herein result in a reduction in DHEAS levels. In some embodiments, the methods described herein result in a reduction in testosterone (T) levels. In some embodiments, the methods described herein result in a reduction in DHT levels. In some embodiments, the methods described herein result in a reduction in 11OHA4 levels. In some embodiments, the methods described herein result in a reduction in 11OHT levels. In some embodiments, the methods described herein result in a reduction in 11KA4 levels. In some embodiments, the methods described herein result in a reduction in 11KT levels.
[0162] Further, in some embodiments, the methods described herein result in a maintained reduction in 17-OHP, A4, ACTH, DHEA, DHEAS, T, DHT, 11OHA4, 11OHT, 11KA4, and / or 11KT levels. In some embodiments, the reduction in 17-OHP, A4, ACTH, DHEA, DHEAS, T, DHT, 11OHA4, 11OHT, 11KA4, and / or 11KT levels can last for at least 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks , 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 2 years, 5 years, 10 years, 15 years, 20 years, 25 years, 30 years, 35 years, 40 years, 45 years, 50 years, 55 years, 60 years, 65 years, 70 years, 75 years, 80 years, 85 years, 90 years, 95 years, or 100 years.
[0163] In some embodiments, the methods described herein result in a reduction in DHEAS levels. In some embodiments, DHEAS levels are reduced by at least about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% from baseline. The baseline level of DHEAS can be measured in a subject prior to starting a treatment disclosed herein. In some embodiments, DHEAS levels are reduced by at least 5% from baseline. In some embodiments, the decreased DHEAS levels from baseline are maintained for at least about 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, or 30 weeks.
[0164] Further, in some embodiments, the methods described herein result in a maintained reduction in 17-OHP, A4, ACTH, T, DHT, 11OHA4, 11OHT, 11KA4, and / or 11KT levels. In some embodiments, the reduction in 17-OHP, A4, ACTH, T, DHT, 11OHA4, 11OHT, 11KA4, and / or 11KT levels can be sustained for at least 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours, 55 hours 3 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 2 years, 5 years, 10 years, 15 years, 20 years, 25 years, 30 years, 35 years, 40 years, 45 years, 50 years, 55 years, 60 years, 65 years, 70 years, 75 years, 80 years, 85 years, 90 years, 95 years, or 100 years.
[0165] In some embodiments, disclosed herein is a method for treating PCOS in a subject in need thereof, and the method further comprises obtaining a source of excess androgen; and administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof. In some embodiments, obtaining a source of excess androgen comprises measuring the main source of excess androgen produced in a subject with PCOS. In some embodiments, the main source is the ovary. In some embodiments, the main source is the adrenal gland. In some embodiments, the main source is both the ovary and the adrenal gland. In some embodiments, the main source is an organ capable of producing androgen.
[0166] In some embodiments, a subject may be administered tadalafil or any other suitable hormone or compound to obtain an ACTH response in order to test for adrenal hyperandrogenism. In some embodiments, tadalafil is administered at a dose of at least about 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, or 250 μg / m 2In some embodiments, the tadalafil is administered at a dose within a range between about the doses disclosed herein. In some embodiments, the tadalafil is administered at a dose of up to about 250, 200, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 4, 3, 2, 1 μg / m 2 dosage administration.
[0167] In some embodiments, the subject will receive treatment for about 1 week to about 40 weeks. In some embodiments, the subject will receive treatment for about 2 weeks to about 39 weeks. In some embodiments, the subject will receive treatment for about 3 weeks to about 38 weeks. In some embodiments, the subject will receive treatment for about 4 weeks to about 36 weeks. In some embodiments, the subject will receive treatment for about 1 month to 12 months. In some embodiments, the subject will receive treatment for about 10 months to 10 years. In some embodiments, the subject will receive treatment for about 1 month to 10 years. In some embodiments, the subject will receive treatment for about 10 months to 20 years. In some embodiments, the subject will receive treatment for about 1 month to 20 years. In some embodiments, the subject will receive treatment for about 10 months to 30 years. In some embodiments, the subject will receive treatment for about 1 month to 30 years. In some embodiments, the subject will receive treatment for about 10 months to 40 years. In some embodiments, the subject will receive treatment for about 1 month to 40 years. In some embodiments, the subject will receive treatment for about 10 months to 50 years. In some embodiments, subjects will receive treatment for about 1 month to 50 years.
[0168] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is selected from: antalamine hydrochloride, CP-154,526, CP-376395 hydrochloride, NBI 27914 hydrochloride, NBI 35965 hydrochloride, NGD 98-2 hydrochloride, pexaserfon, R 121919 hydrochloride, SSR125543 (Coraserfon) and SN003.
[0169] In some embodiments, the CRF1 antagonist is a compound of formula (I):
[0170]
[0171] or a pharmaceutically acceptable salt thereof, wherein:
[0172] R 1 and R 2 are independently ethyl or n-propyl;
[0173] R 3is hydrogen, F, Cl, Br, methyl, trifluoromethyl or methoxy; and R 4 For hydrogen, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, And R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3-.
[0174] In some embodiments, R 3 is F, Cl, Br, methyl or trifluoromethyl. In some embodiments, R 3 It is Cl, Br or methyl.
[0175] In some embodiments, R 4 Br, -NR a R b -NR a R b , pyridin-4-yl, morpholin-4-yl or In some embodiments, R 4 is morpholin-4-yl or In some embodiments, R 4 For hydrogen, Br, -NR a R b , and R a and R b are independently C1-C3 alkyl.
[0176] In some embodiments, the compound is:
[0177] or a pharmaceutically acceptable salt thereof.
[0178] In some embodiments, the compound is:
[0179] or a pharmaceutically acceptable salt thereof.
[0180] In some embodiments, the compound is:
[0181] or a pharmaceutically acceptable salt thereof.
[0182] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 10 mg to about 200 mg total daily dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 200 mg total daily dose.
[0183] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 150 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 100 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 50 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 40 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 30 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 25 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 20 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 15 mg daily total dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 10 mg total daily dose. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is administered to a subject at a dose of about 5 mg total daily dose.
[0184] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is in the form of microparticles. In some embodiments, the average size of the microparticles is about 1 μm to about 20 μm. In some embodiments, the average size of the microparticles is about 5 μm to about 15 μm. In some embodiments, the average size of the microparticles is less than about 10 μm.
[0185] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition. In some embodiments, the steroid or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition.
[0186] In some embodiments, the pharmaceutical composition is in the form of a capsule or tablet. In some embodiments, the capsule is a hard gelatin capsule. In some embodiments, the capsule is a soft gelatin capsule. In some embodiments, the capsule is formed using a material selected from natural gelatin, synthetic gelatin, pectin, casein, collagen, protein, modified starch, polyvinyl pyrrolidone, acrylic acid polymers, cellulose derivatives, and any combination thereof.
[0187] In some embodiments, the pharmaceutical composition does not contain additional excipients. In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition is in the form of a tablet. In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
[0188] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 1 to about 8 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 2 to about 7 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 2 to about 6 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 3 to about 5 hours in a subject.
[0189] In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 8 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 7 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 6 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 5 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 4 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 3 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 2 hours in a subject. In some embodiments, the CRF1 antagonist or a pharmaceutically acceptable salt is formulated as a capsule or tablet to provide a Tmax of about 1 hour in a subject.
[0190] In some embodiments, the methods described herein include administering a pharmaceutical composition comprising a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, once a month, twice a month, three times a month, once a week, twice a week, three times a week, once every two days, once a day, twice a day, three times a day, or four times a day. In some embodiments, the methods described herein administer a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, once a day. In some embodiments, the methods described herein administer a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, twice a day.
[0191] In some embodiments, the methods described herein include administering about 1 mg to about 2000 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, daily. In some embodiments, the CRF1 antagonist or pharmaceutically acceptable salt is administered at a dose of about 50 mg / day to about 1600 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 1500 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 1400 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 1300 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 1200 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 1100 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 1000 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 900 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day to about 800 mg / day. In some embodiments, compound 3 is administered at a dose of about 60 mg / day to about 800 mg / day. In some embodiments, compound 3 is administered at a dose of about 70 mg / day to about 800 mg / day. In some embodiments, compound 3 is administered at a dose of about 80 mg / day to about 800 mg / day. In some embodiments, compound 3 is administered at a dose of about 90 mg / day to about 800 mg / day. In some embodiments, compound 3 is administered at a dose of about 100 mg / day to about 800 mg / day. In some embodiments, compound 3 is administered at a dose of about 100 mg / day to about 700 mg / day. In some embodiments, compound 3 is administered at a dose of about 100 mg / day to about 600 mg / day. In some embodiments, compound 3 is administered at a dose of 150 mg / day to about 600 mg / day. In some embodiments, compound 3 is administered at a dose of 200 mg / day to about 600 mg / day. In some embodiments, compound 3 is administered at a dose of 200 mg / day to about 500 mg / day. In some embodiments, compound 3 is administered at a dose of 200 mg / day to about 400 mg / day. In some embodiments, compound 3 is administered at a dose of 25 mg / day to about 200 mg / day.
[0192] In some embodiments, compound 3 is administered at a dose of about 500 mg / day. In some embodiments, compound 3 is administered at a dose of about 400 mg / day. In some embodiments, compound 3 is administered at a dose of about 300 mg / day. In some embodiments, compound 3 is administered at a dose of about 200 mg / day. In some embodiments, compound 3 is administered at a dose of about 150 mg / day. In some embodiments, compound 3 is administered at a dose of about 100 mg / day. In some embodiments, compound 3 is administered at a dose of about 50 mg / day.
[0193] In some embodiments, about 50 mg to about 1600 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 100 mg to about 1600 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 200 mg to about 1600 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 200 mg to about 1200 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 200 mg to about 1000 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 200 mg to about 800 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 100 mg to about 800 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 200 mg to about 800 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 100 mg to about 600 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 200 mg to about 600 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 300 mg to about 600 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 100 mg to about 400 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 200 mg to about 400 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, about 300 mg to about 400 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily.
[0194] In some embodiments, less than about 2000 mg of CRF1 antagonist or pharmaceutically acceptable salt, or pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 1800 mg of CRF1 antagonist or pharmaceutically acceptable salt, or pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 1600 mg of CRF1 antagonist or pharmaceutically acceptable salt, or pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 1400 mg of CRF1 antagonist or pharmaceutically acceptable salt, or pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 1200 mg of CRF1 antagonist or pharmaceutically acceptable salt, or pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 1000 mg of CRF1 antagonist or pharmaceutically acceptable salt, or pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 800 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 600 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 500 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 400 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 300 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily. In some embodiments, less than about 200 mg of a CRF1 antagonist or a pharmaceutically acceptable salt, or a pharmaceutically acceptable salt or solvate thereof, is administered daily.
[0195] In some embodiments, the methods described herein include administering a pharmaceutical composition described herein, wherein the subject is in a fed state. In some embodiments, the methods described herein include administering a pharmaceutical composition described herein, wherein the subject is in a fasted state.
[0196] In some embodiments, the methods described herein comprise administering a pharmaceutical composition described herein prior to bedtime.
[0197] In some embodiments, the methods described herein include administering a pharmaceutical composition described herein less than about 4 hours before going to bed. In some embodiments, the methods described herein include administering a pharmaceutical composition described herein less than about 3 hours before going to bed. In some embodiments, the methods described herein include administering a pharmaceutical composition described herein less than about 2 hours before going to bed. In some embodiments, the methods described herein include administering a pharmaceutical composition described herein less than about 1 hour before going to bed. In some embodiments, the methods described herein include administering a pharmaceutical composition described herein less than about 30 minutes before going to bed.
[0198] In some embodiments, the methods described herein comprise administering a pharmaceutical composition described herein in the evening.
[0199] In some embodiments, the methods described herein comprise administering a pharmaceutical composition described herein at about 11 p.m. In some embodiments, the methods described herein comprise administering a pharmaceutical composition described herein at about 10 p.m. In some embodiments, the methods described herein comprise administering a pharmaceutical composition described herein at about 9 p.m. In some embodiments, the methods described herein comprise administering a pharmaceutical composition described herein at about 8 p.m.
[0200] In some embodiments, the methods described herein include administering the pharmaceutical compositions described herein in combination with eflornithine and / or a retinoid. In some embodiments, the methods described herein include administering the pharmaceutical compositions described herein in combination with a contraceptive containing an androgen receptor blocker (such as cyproterone acetate, spironolactone, flutamide, or a 5α-reductase inhibitor).
[0201] In some embodiments, the level of DHEA, DHEAS, A4, 11OHA4, T, 11OHT, DHT and / or ACTH in a subject is determined from a biological sample of the subject. In some embodiments, the biological sample is selected from blood, blood fractions, plasma, serum, urine, other types of body secretions and saliva. In some embodiments, the biological sample is obtained non-invasively.
[0202] In some embodiments, the subject is a pediatric patient. In some embodiments, the subject is a teenager. In some embodiments, the subject is about 8 to about 18 years old. In some embodiments, the subject is an adult patient. In some embodiments, the subject is about 18 to about 55 years old. In some embodiments, the subject is about 18 to about 50 years old.
[0203] In some embodiments, the steroid and the CRF1 antagonist are administered simultaneously. In some embodiments, the steroid and the CRF1 antagonist are administered in one pharmaceutical composition. In some embodiments, the steroid and the CRF1 antagonist are administered simultaneously in separate pharmaceutical compositions. In some embodiments, the steroid and the CRF1 antagonist are administered sequentially.
[0204] The present invention provides embodiments including but not limited to the following:
[0205] 1. A method for treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH+FAH) in a subject in need thereof, comprising administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof.
[0206] 2. A method for treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, comprising administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof.
[0207] 3. The method according to any one of embodiments 1 to 2, wherein the CRF1 antagonist is a compound of formula (I):
[0208]
[0209] or a pharmaceutically acceptable salt thereof, wherein:
[0210] R 1 and R 2 are independently ethyl or n-propyl;
[0211] R 3 is hydrogen, F, Cl, Br, methyl, trifluoromethyl or methoxy;
[0212] R 4 For hydrogen, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl,
[0213] R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3.
[0214] 4. The method according to embodiment 3, wherein R 3 is F, Cl, Br, methyl or trifluoromethyl.
[0215] 5. The method according to embodiment 3 or embodiment 4, wherein R 3 It is Cl or Br.
[0216] 6. The method according to any one of embodiments 4 to 5, wherein R 4 For-NR a R b , pyridin-4-yl, morpholin-4-yl or
[0217] 7. The method according to any one of embodiments 4 to 6, wherein R 4 is morpholin-4-yl or
[0218] 8. The method according to any one of embodiments 4 to 6, wherein R 4 For-NR a R b , and R a and R b are independently C1-C3 alkyl.
[0219] 9. The method according to embodiment 4, wherein the CRF1 antagonist or a pharmaceutically acceptable salt thereof is 3-[4-bromo-2-(2-methyl-2H-[1,2,4]triazol-3-yl)-thiazol-5-yl]-2,5-dimethyl-7-(1-propyl-butyl)-pyrazolo[1,5-a]pyrimidine.
[0220] 10. The method according to embodiment 4, wherein the CRF1 antagonist or a pharmaceutically acceptable salt thereof is 3-(4-bromo-2-(2-methyl-2H-[1,2,4]triazol-3-yl)-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine.
[0221] 11. The method according to embodiment 4, wherein the CRF1 antagonist or a pharmaceutically acceptable salt thereof is 3-(4-chloro-2-morpholin-4-yl-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine.
[0222] 12. The method according to embodiment 4, wherein the CRF1 antagonist is or a pharmaceutically acceptable salt thereof.
[0223] 13. The method according to embodiment 4, wherein the CRF1 antagonist is or a pharmaceutically acceptable salt thereof.
[0224] 14. The method according to embodiment 4, wherein the compound is or a pharmaceutically acceptable salt thereof.
[0225] 15. The method according to any one of embodiments 1 to 2, wherein the CRF1 antagonist or a pharmaceutically acceptable salt thereof is selected from: antalamine hydrochloride, CP-154,526, CP-376395 hydrochloride, NBI 27914 hydrochloride, NBI35965 hydrochloride, NGD 98-2 hydrochloride, pexaserfon, R 121919 hydrochloride, SSR125543 (coresefen) and SN003.
[0226] 16. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 5 mg to about 400 mg.
[0227] 17. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 300 mg.
[0228] 18. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 200 mg.
[0229] 19. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 150 mg.
[0230] 20. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 100 mg.
[0231] 21. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or a pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 75 mg.
[0232] 22. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 50 mg.
[0233] 23. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 25 mg.
[0234] 24. The method of any one of embodiments 1 to 15, wherein the CRF1 antagonist or pharmaceutically acceptable salt is administered to the subject at a total daily dose of about 10 mg.
[0235] 25. The method of any one of embodiments 1 to 24, wherein the CRF1 antagonist or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical composition.
[0236] 26. The method of any one of embodiments 1 to 25, wherein adrenocorticotropic hormone (ACTH) levels are reduced by at least 5% from baseline.
[0237] 27. The method of any one of embodiments 1 to 25, wherein adrenocorticotropic hormone (ACTH) levels are reduced by at least 10% from baseline.
[0238] 28. The method of any one of embodiments 1 to 25, wherein dehydroepiandrosterone sulfate (DHEAS) levels are reduced by at least 5% from baseline.
[0239] 29. The method of any one of embodiments 1 to 25, wherein the level of dehydroepiandrosterone sulfate (DHEAS) is reduced by at least 10% from baseline.
[0240] 30. The method of any one of embodiments 1 to 25, wherein androstenedione (A4) levels are reduced by at least 5% from baseline.
[0241] 31. The method of any one of embodiments 1 to 25, wherein androstenedione (A4) levels are reduced by at least 10% from baseline.
[0242] 32. The method of any one of embodiments 1 to 25, wherein 11β-hydroxyandrostenedione (11OHA4) levels are reduced by at least 5% from baseline.
[0243] 33. The method of any one of embodiments 1 to 25, wherein 11β-hydroxyandrostenedione (11OHA4) levels are reduced by at least 10% from baseline.
[0244] 34. The method of any one of embodiments 1 to 25, wherein 11β-hydroxytestosterone (11OHT) levels are reduced by at least 5% from baseline.
[0245] 35. The method of any one of embodiments 1 to 25, wherein 11β-hydroxytestosterone (11OHT) levels are reduced by at least 10% from baseline.
[0246] 36. The method of any one of embodiments 25 to 35, wherein the reduced ACTH, DHEAS, A4, 11OHA4 or 11OHT levels compared to baseline are maintained for at least 24 hours.
[0247] 37. The method of any one of embodiments 25 to 35, wherein the reduced ACTH, DHEAS, A4, 11OHA4 or 11OHT levels from baseline are maintained for at least 4 weeks.
[0248] 38. A method for treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, comprising administering a pharmaceutical composition comprising Compound 3:
[0249] or a pharmaceutically acceptable salt or solvate thereof.
[0250] 39. A method for treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH+FAH) in a subject in need thereof, comprising administering a pharmaceutical composition comprising compound 3:
[0251] or a pharmaceutically acceptable salt or solvate thereof.
[0252] 40. The method of embodiment 38 or embodiment 39, wherein Compound 3 is administered at a dose of about 1 mg / day to about 200 mg / day.
[0253] 41. The method according to any one of embodiments 38 to 40, wherein the pharmaceutical composition comprises about 1 mg to about 400 mg of Compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0254] 42. The method of embodiment 41, wherein the pharmaceutical composition comprises about 25 mg of Compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0255] 43. The method of embodiment 41, wherein the pharmaceutical composition comprises about 50 mg of Compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0256] 44. The method of embodiment 41, wherein the pharmaceutical composition comprises about 75 mg of Compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0257] 45. The method of embodiment 41, wherein the pharmaceutical composition comprises about 100 mg of Compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0258] 46. The method of embodiment 41, wherein the pharmaceutical composition comprises about 200 mg of Compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0259] 47. The method of embodiment 41, wherein the pharmaceutical composition comprises about 300 mg of Compound 3 or a pharmaceutically acceptable salt or solvate thereof.
[0260] 48. The method of any one of embodiments 1 to 47, wherein the pharmaceutical composition is in the form of microparticles.
[0261] 49. The method of embodiment 48, wherein the average size of the microparticles is about 1 μm to about 20 μm.
[0262] 50. The method of embodiment 48, wherein the average size of the microparticles is about 5 μm to about 15 μm.
[0263] 51. The method of embodiment 48, wherein the average size of the microparticles is less than about 10 μm.
[0264] 52. The method of any one of embodiments 1 to 47, wherein the pharmaceutical composition is in the form of a capsule or a tablet.
[0265] 53. The method of embodiment 52, wherein the capsule is a hard gelatin capsule.
[0266] 54. The method of embodiment 52, wherein the capsule is a soft gelatin capsule.
[0267] 55. A method according to any one of embodiments 52 to 54, wherein the capsule is formed using a material selected from natural gelatin, synthetic gelatin, pectin, casein, collagen, protein, modified starch, polyvinylpyrrolidone, acrylic polymers, cellulose derivatives and any combination thereof.
[0268] 56. The method of any one of embodiments 52 to 54, wherein the pharmaceutical composition contains no additional excipients.
[0269] 57. The method of any one of embodiments 52 to 54, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
[0270] 58. The method of embodiment 52, wherein the pharmaceutical composition is in the form of a tablet.
[0271] 59. The method of embodiment 58, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
[0272] 60. The method of any one of embodiments 1 to 59, wherein the subject is a pediatric patient.
[0273] 61. The method of any one of embodiments 1 to 59, wherein the subject is between about 9 and about 18 years old.
[0274] 62. The method of any one of embodiments 1 to 59, wherein the subject is between about 8 and about 55 years old.
[0275] 63. A method according to any one of embodiments 1 to 59, wherein the subject is an adult patient.
[0276] 64. The method of any one of embodiments 1 to 63, wherein the subject receives treatment for about 2 weeks to about 36 weeks.
[0277] 65. The method of any one of embodiments 1 to 63, wherein the subject receives treatment for about 1 month to 12 months.
[0278] 66. The method of any one of embodiments 1 to 63, wherein the subject receives treatment for about 10 months to 50 years.
[0279] Example
[0280] The following examples further illustrate the present invention, but should not be construed as limiting the scope of the present invention in any way. Specifically, the processing conditions are merely exemplary, and those of ordinary skill in the art can easily change the processing conditions.
[0281] Unless otherwise specified herein or otherwise clearly contradictory to the context, all methods described herein may be performed in an appropriate order. Unless otherwise stated, the use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present invention and is not intended to limit the scope of the present invention. Unless otherwise specified, the meanings of the technical terms and scientific terms used herein are the same as those commonly understood by those skilled in the art to which the present invention belongs.
[0282] Example 1 - Reduction of DHEAS Levels in Subjects with Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens
[0283] Compound 3 is being studied in a double-blind, proof-of-concept study to evaluate the safety and efficacy of repeated doses of Compound 3 in adults with elevated adrenal androgens, PCOS-FAH, or PCOS-FAH+FOH. Following screening, eligible subjects with elevated adrenal androgens documented by elevated DHEAS will be randomized to either Compound 3 dose escalation or matching placebo.
[0284] The study is planned as a phase 3 study, with a duration of 4 weeks for phases 1 and 2, 8 weeks for phase 3, and a total treatment duration of 16 weeks. Subjects randomly assigned to the compound 3 dose escalation group will receive 50-mg, 100-mg or 200 mg escalating doses based on reaching the DHEAS positive response criteria in each treatment period. The dose of subjects who did not meet the criteria in the previous period will be increased to the next highest dose. Subjects who meet the criteria will maintain their current dose level. Placebo subjects will remain on placebo throughout the 16 weeks.
[0285] The group consisted of approximately 40 patients who received compound 3 or matching placebo daily for up to 16 weeks. Compound 3 was administered as an oral daily dose. Patients received either PK / PD assessments or PD-only assessments approximately every 2 weeks. Follow-up clinic visits were performed 30 days after the last dose.
[0286] Study Design
[0287] Study type: Interventional
[0288] Main purpose: Treatment
[0289] Research phase: Phase 2
[0290] Interventional study model: Randomized
[0291] Number of groups: 2
[0292] Blind: Blind study drug
[0293] Allocation: Random (1:1)
[0294] ·Inclusion: 40
[0295] Groups and Interventions:
[0296]
[0297] Outcome Metrics
[0298] Main outcome measures:
[0299] 1. Safety and tolerability of compound 3 in patients with elevated adrenal androgens (adverse reactions, serious adverse reactions, clinical laboratory parameters, etc.)
[0300] [Time frame: 16 weeks]
[0301] Secondary outcome measures:
[0302] 2. Proportion of the object:
[0303] a. Change in dehydroepiandrosterone sulfate (DHEAS) from baseline ≥ 30%
[0304] b.DHEAS < upper limit of normal (ULN)
[0305] c.DHEAS < 75th percentile of normal range (Q3)
[0306] [Time frame: 4 to up to 16 weeks]
[0307] 3. Pharmacokinetics of Compound 3
[0308] [Time frame: 4 weeks]
[0309] Exploratory outcome measures:
[0310] 4. Changes in PD markers: changes in cortisol, ACTH, DHEAS, DHEA, A4, T, 17-OHP, 11OHA4, 11OHT, 11KA4, 11KT
[0311] [Time frame: up to 16 weeks]
[0312] Eligibility criteria
[0313] Minimum age: 18 years old
[0314] Maximum age: 30 years old
[0315] Gender: Female only
[0316] Based on gender: Yes
[0317] Accept healthy volunteers: No
[0318] Standard: Included
[0319] standard:
[0320] Inclusion criteria:
[0321] Female subjects aged 18 to 30 years, inclusive
[0322] Subjects must have PCOS documented according to NIH (1990) criteria
[0323] BMI ≤ 38 kg / m 2
[0324] DHEAS level > age-matched reference ULN at screening
[0325] Evidence of DHEA hyperresponsiveness to ACTH stimulation during screening
[0326] Exclusion criteria:
[0327] BMI>38 kg / m 2
[0328] Suffering from PCOS-FOH
[0329] HbA1c > 6.5% or fasting blood glucose > 126 mg / dL
[0330] A history of bilateral adrenalectomy or hypopituitarism
[0331] History of allergic or hypersensitivity reaction to tildacerfont or any other CRF1 receptor antagonist
[0332] · Clinically significant unstable medical condition, illness or chronic disease
[0333] Clinically significant uncontrolled mental disorder
[0334] Clinically significant abnormal laboratory findings or evaluations
[0335] Pregnant or breastfeeding women
[0336] Use of any other investigational drug within 30 days
[0337] · Inability to understand and comply with study procedures, inability to comprehend risks, and / or unwillingness to provide written informed consent.
[0338] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. The present invention is not intended to be limited by the specific examples provided in the specification. Although the present invention has been described with reference to the above description, the description and illustration of the embodiments herein are not meant to be understood in a limiting sense. Without departing from the present invention, those skilled in the art will now think of many variations, changes and substitutions. In addition, it should be understood that all aspects of the present invention are not limited to the specific depictions, configurations or relative proportions set forth herein, which will depend on various conditions and variables. It should be understood that various alternatives to the embodiments of the present invention described herein can be adopted when practicing the present invention. Therefore, it is conceivable that the present invention will also cover any such alternatives, modifications, variations or equivalents. The following claims are intended to define the scope of the present invention and are thus covered within the scope of these claims and their equivalents Methods and structures.
Claims
1. A method for treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH+FAH) in a subject in need thereof, comprising administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof.
2. A method for treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, comprising administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof.
3. The method according to any one of claims 1 to 2, wherein the CRF1 antagonist is a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 are independently ethyl or n-propyl; R 3 is hydrogen, F, Cl, Br, methyl, trifluoromethyl or methoxy; R 4 For hydrogen, Br, -NR a R b , methoxymethyl, n-butyl, acetylamino, pyridin-4-yl, morpholin-4-yl, R a and R b are independently hydrogen, C1-C3 alkyl, -CH2CH2NH2, -CH2CH2NHC(O)OC(CH3)3 or -CH2CH2NHCH2CH2CH3.
4. The method according to claim 3, wherein R 3 is F, Cl, Br, methyl or trifluoromethyl.
5. The method according to claim 3 or claim 4, wherein R 3 It is Cl or Br.
6. The method according to any one of claims 4 to 5, wherein R 4 For-NR a R b , pyridin-4-yl, morpholin-4-yl or 7. The method according to any one of claims 4 to 6, wherein R 4 is morpholin-4-yl or 8. The method according to any one of claims 4 to 6, wherein R 4 For-NR a R b , and R a and R b are independently C1-C3 alkyl.
9. A method for treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, comprising administering a pharmaceutical composition comprising compound 3: or a pharmaceutically acceptable salt or solvate thereof.
10. A method for treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH+FAH) in a subject in need thereof, comprising administering a pharmaceutical composition comprising compound 3: or a pharmaceutically acceptable salt or solvate thereof.
